The story in the movie really happened in real life. In the last decade of 2004, the protagonist prototype Lu Yong helped leukemia patients to buy targeted drug Gleevec on a large scale, and many acquaintances around him bought Indian generic drugs. Who can tell the grievances behind China's "high-priced medicine"? Patients have to sadly choose "cheap" Indian generic drugs and seize the last straw.
Why are Indian medicines cheap? Why did generic drugs develop? What can we change? Taking history as a mirror, Yunfeng Finance uses comics to sort out the development history of generic drugs in India, and maybe we can find the answer from it. In recent years, China's pharmaceutical industry has risen, and relevant policies are in full swing. I believe that China's medicine will also walk out of its own broad road.
India is known as the "world pharmacy" and one of the major drug exporters in the world. About one-fifth of the world's generic drugs come from India for the following reasons: First, India's pharmaceutical industry is relatively developed, and pharmaceutical companies have relatively strong research and development capabilities, which is the basic skill of Indian drug imitation.
Second, the relevant policies are relatively loose, even at the expense of issuing compulsory license certificates, giving a green light to domestic generic drugs. To put it bluntly, this medicine is too expensive. I don't force domestic companies to produce generic drugs, and most Indians can't afford high medical expenses.
In particular, some imported anticancer drugs are expensive, such as Gleevec produced by Novartis in Switzerland, which is used to treat chronic myeloid leukemia. When converted into RMB, the cost of drugs alone will be 23,500 RMB a month, which ordinary people simply cannot afford. Gleevec has patents in many countries around the world, but the Indian government has not granted Gleevec a patent. What is the reason? This is our third point.